1-pyridin-3-ylethanone

We are 1-pyridin-3-ylethanone CAS:350-03-8 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:1-pyridin-3-ylethanone
CAS.NO:350-03-8
Synonyms:1-pyridin-3-ylethanone
3-Acetylpyridine
Methyl pyridin-3-yl ketone
3-Pyridyl methyl ketone
Ketone,methyl 3-pyridyl
Methyl 3-pyridyl ketone
 
Physical and Chemical Properties:
Density 1.1±0.1 g/cm3
Boiling Point 220.8±13.0 °C at 760 mmHg
Melting Point 11-13 °C(lit.)
Molecular Formula C7H7NO
Molecular Weight 121.137
Flash Point 150.0±0.0 °C
 
Specification:
Appearance:Colorless to yellow liquid
Assay:≥99.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Flavors and fragrances intermediate

1-pyridin-3-ylethanone


Related News: Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added.5- (3-fluorofenil) -2-metilpiridina CAS:713143-67-0 Remogliflozin is economical than other similar agents currently available in sodium glucose co-transporter-2 (SGLT2) inhibitors class, which shall help for its better access among middle and low socio-economic strata of the society, he added.1-(3,4-dihydro-2H-pyrrol-2-yl)ethanone Capacity: the bottleneck of business growth, expanding capacity and increasing utilization become a trend. Capacity is the core factor that determines the supply capacity of API companies. Insufficient capacity will cause companies to selectively complete orders and produce varieties, limiting the expansion of API products and market development.132628-16-1 At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world.This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.

Related Products
Product Name
4-bromo-2-nitro-1-(trifluoromethyl)benzene View Details
(2,5-dioxopyrrolidin-1-yl) 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetate View Details
Ethyl 4,5-bis(2-methoxyethoxy)-2-nitrobenzoate View Details
ethyl 3-amino-5-methyl-1H-pyrazole-4-carboxylate manufacturer 4-Amino-3-bromobenzonitrile manufacturer 1-Propyl-1H-imidazole manufacturer 1-Fluoro-10-chlorodecane manufacturer Maleic acid polymer Cas:26099-09-2 manufacturer